Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01196390 · OUTCOME

Quality-adjusted Survival

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer · Source last updated 2026-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From randomization to last follow-up. Maximum follow-up at time of primary outcome measure analysis was 8 years.

Analysis population: The protocol states that this outcome measure will be analyzed only if primary outcome results are positive, i.e. support the primary hypothesis of this study. Therefore no participants were analyzed for this outcome measure.

Groups in this outcome

Chemoradiation and Trastuzumab

Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab

Chemoradiation

Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemoradiation and Trastuzumab0
Chemoradiation0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab
    id
    OG000
    title
    Chemoradiation and Trastuzumab
  2. description
    Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery
    id
    OG001
    title
    Chemoradiation
population Description
The protocol states that this outcome measure will be analyzed only if primary outcome results are positive, i.e. support the primary hypothesis of this study. Therefore no participants were analyzed for this outcome measure.
reporting Status
POSTED
time Frame
From randomization to last follow-up. Maximum follow-up at time of primary outcome measure analysis was 8 years.
title
Quality-adjusted Survival
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice